Is VYNE diluting shareholders?

Read three numbers together: shares outstanding over time (2.7M as of 2026-08-10), warrants that can convert into new shares (550 reported), and how much cash runway remains (~8.305156382079458 months). A company short on cash with live registrations is structurally likely to issue shares.

Where do these numbers come from?

SEC EDGAR only: the XBRL company-facts API for shares, warrants and cash, and filing metadata for registrations and pricings. Every figure shows its source form, and nothing here is estimated by us beyond the arithmetic stated next to it.

Why might a warrant tranche be missing from the table?

The tranche table is built from the dimensions the company tagged in its own 10-Q or 10-K XBRL. A tranche the filer chose not to dimension does not appear, and its absence proves nothing: the exhibits remain the ground truth. Everything shown carries the filing it came from.

Dilution profile // every instrument, one screen, from SEC filings

Yarrow Bioscience, Inc. (VYNE)

CIK 1566044 · all EDGAR filings →

Overall dilution risk

HIGHworst of 4 computed signals (offering ability)

= the worst band among the computed sub-ratings, no hidden weighting

Offering ability

HIGHS-3 on file 2024-03-01

= is there a registration (S-1/S-3 family) on file without a later withdrawal

no structured fee data on the live registrations, so this is a yes/no, not a size

Overhead supply

LOWwarrants = 0% of O/S

= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)

warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this

Historical dilution

LOW-81% O/S in 3y

= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative

a reverse-split-sized cliff is in this window; read the chart

Cash need

MEDIUM~8.3 months of runway

= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

the company itself flagged going-concern doubt

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

Latest: 2.7M shares as of Aug 10, 2026 (10-Q). Share count fell from 58.0M to 3.3M between Nov 1, 2022 and Mar 1, 2023, a pattern consistent with a reverse split (roughly 1-for-18); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.

Cash runway

Going-concern warning

auditor flagged substantial doubt

The company itself flagged going-concern doubt in a filing.

Full breakdown: cash runway tool · source filing →

Warrants

Warrants outstanding: 550 underlying shares, as reported Jun 30, 2026 (10-Q).

Reported exercise price: $420 (aggregate figure as tagged; individual tranches vary).

Rough fully diluted estimate: 2.7M = 2.7M O/S + 550 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Aug 13, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding	2.7M	Aug 10, 2026
+ Warrants (aggregate, as tagged) (if exercised)	550	Jun 30, 2026
Fully diluted estimate	2.7M	+0.0% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

S-3Mar 1, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

S-3Nov 13, 2023no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 2 executed · 0 registered.

EXECUTEDJul 28, 2026Unregistered share sale disclosed (8-K item 3.02)8-K →

UPDATEJun 15, 2026Prospectus update — often a resale registration, not necessarily new capital424B3 →

EFFECTIVEJun 15, 2026SEC declared a registration effective — selling can beginEFFECT →

EXECUTEDDec 17, 2025Unregistered share sale disclosed (8-K item 3.02)8-K →

EFFECTIVEMar 14, 2024SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDMar 1, 2024S-3 registration — capacity to sell shares, not a sale yetS-3 →

UPDATENov 22, 2023Prospectus update — often a resale registration, not necessarily new capital424B3 →

EFFECTIVENov 22, 2023SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDNov 13, 2023S-3 registration — capacity to sell shares, not a sale yetS-3 →

EXECUTEDOct 30, 2023Unregistered share sale disclosed (8-K item 3.02)8-K →

EXECUTEDMay 12, 2022Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →

EXECUTEDMar 15, 2022Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full VYNE workspace